首页> 美国卫生研究院文献>Aging (Albany NY) >Exploring the mechanism of resistance to sorafenib in two hepatocellular carcinoma cell lines
【2h】

Exploring the mechanism of resistance to sorafenib in two hepatocellular carcinoma cell lines

机译:探讨两种肝细胞癌细胞含量抗索拉非尼的机制

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Sorafenib has long been the only approved systemic therapy for advanced hepatocellular carcinoma (HCC), but most patients show primary or acquired drug resistance. In the present study, RNA was extracted from sorafenib-resistant and -sensitive clones of the HCC cell lines HepG2 and Huh7. Protein-protein interaction networks of the up- and down-regulated genes common to the two sorafenib-resistant cell lines were extracted and subjected to modular analysis in order to identify functional modules. Functional enrichment analysis showed the modules were involved in different biological processes and pathways. These results indicate that sorafenib resistance in HCC is complicated and heterogeneous. The potential regulators of each functional module, including transcription factors, microRNAs and long non-coding RNAs, were explored to construct a comprehensive transcriptional regulatory network related to sorafenib resistance in HCC. Our results provide new insights into sorafenib resistance of HCC at the level of transcriptional regulation.
机译:Sorafenib长期以来一直是唯一批准的肝细胞癌(HCC)的批准的全身治疗,但大多数患者显示初级或获得的耐药性。在本研究中,RNA从HCC细胞系HepG2和HuH7的索拉苯抗性和 - 密封克隆中提取。提取两种Sorafenib抗性细胞系共同的上调基因的蛋白质 - 蛋白质相互作用网络,并进行模块化分析以识别功能模块。功能性富集分析显示模块涉及不同的生物过程和途径。这些结果表明,HCC中的索拉非尼抗性复杂且异质。探讨了每个功能模块的潜在调节因子,包括转录因子,MicroRNA和长期非编码RNA,以构建与HCC中的索拉非尼抗性相关的综合转录监管网络。我们的结果在转录调节水平下对HCC的索拉非尼抗性提供了新的见解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号